Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
Plasma Exchange
A Clear Road to Results for MG and GBS Patients
Overview MG GBS How It Works Safety Resources References

GBS: A Clear Road to Recovery

Patients treated early with TPE required less mechanical ventilation, and hospitalisation time was decreased. –Hund et al., 1993

Introducing Plasma Exchange As a First-Line Therapy

The Spectra Optia system is the first therapeutic apheresis system with an indication to treat GBS, and Spectra Optia plasma exchange is recommended as a first-line therapy. Using plasma exchange on the Spectra Optia system to treat patients with GBS results in a rapid clinical response and a fast road to recovery in majority of patients.

Evidence-Based Guidance for Plasma Exchange in GBS


AAN 20111 ASFA 20162 EFNS 20103

Class I (Level A for severe GBS)

Category I (Grade 1A) and Category III (Grade 2C)

Level A

1Cortese I, et al. Neurology. 2011; 76:294-300. 2Schwartz J, et al. J Clin Apher. 2016; 31(3):149-162. 3Elovaara I, et al. Eur J Neurol. 2008; 15:893-908.

GBS: Speed to Response and Recovery

When patients are progressing quickly, a decisive first response is critical. The longer treatment is delayed, the less likely it is that a patient will achieve optimal results. Studies show that GBS patients who receive plasma exchange therapy experience faster response and recovery compared to those receiving only supportive care. (Chevret S et al., 2017)

In addition to a rapid overall recovery time, GBS patients receiving plasma exchange treatment showed the following: (Chevret S et al., 2017)

One or more disability-grade improvements after 4 weeks

Decreased time on a ventilator

Improved functional abilities (for example, faster time to unaided walking and significantly improved grip strength 3 weeks after first plasma exchange)

Increased probability of full muscle strength recovery and decreased probability of severe sequelae and relapse at 1 year

Safety Information


  • No known contraindications for the system's use, except for those associated with all automated apheresis systems
  • The infusion of certain solutions and replacement fluids may be contraindicated in some patients

Possible patient reactions

  • Anxiety, headache, light-headedness, digital and/or facial paresthesia, fever, chills, hematoma, hyperventilation, nausea and vomiting, syncope (fainting), urticaria, hypotension and allergic reactions

Reactions to transfused blood products can include1

  • Fever, circulatory overload, shock, allergic reactions, alloimmunization, graft-versus-host disease and transmission of infection

Restricted to prescription use only

  • Operators must be familiar with the system's operating instructions
  • Procedures must be performed by qualified medical personnel
  • A supervisory practitioner may supervise from a physician office or other nonhospital space that is not officially part of the hospital campus as long as he or she remains immediately available2

1AABB (ed.), et al., Circular of Information for the Use of Human Blood and Blood Components. 2006, tenth edition, Council of Europe Publishing, Seattle, WA.

2American Society for Apheresis. Guidelines for therapeutic apheresis clinical privileges. J Clin Apher. 2007;22(3):181-182.

Download GBS Clinical Summary Sheet
Medical information request
Find an apheresis center near you

International Content. Approved labeling, indications and instructions may vary by country. Reference the Instructions for Use labeling for a complete listing of indications, warnings and precautions.


{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{$index+1}}. {{s.label}}